Skip to main content

Table 3 Comparison of baseline characteristics of patients with vs. without Pneumocystis pneumonia in no-prophylaxis group a

From: Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study

Characteristics PCP group Non-PCP group P-value
Patients (n) 9 552  
Observation period (person-years) 12.5 839.4  
Age (years) 69.5 ± 7.63 57.9 ± 14.1 0.001
Duration of RA (months) 76.3 ± 73.8 112.9 ± 116.5 0.634
DAS28 score (ESR) 6.51 ± 1.28 5.85 ± 1.29 0.060
Coexisting pulmonary disease (%) 77.8 28.1 0.002
Diabetes mellitus (%) 0.00 10.7 0.156
Dose of prednisolone (mg) 8.83 ± 14.9 1.70 ± 2.57 0.004
Glucocorticoids (%)b 88.9 39.9 0.009
Dose of methotrexate (mg/w) 6.56 ± 5.23 7.29 ± 4.10 0.695
Serum level of IgG (mg/dl) 1,600 ± 714 1,620 ± 511 0.660
Serum level of KL-6 (U/ml) 429 ± 218 257 ± 138 0.008
  1. aDAS28: Disease Activity Score in 28 joints; ESR: Erythrocyte sedimentation rate; IgG: immunoglobulin G; PCP: Pneumocystis pneumonia; RA: Rheumatoid arthritis. bGlucocorticoid data are percentages of patients treated with glucocorticoids.
  2. Patient age, the complication of pulmonary disease, the use and dose of glucocorticoids and the serum level of KL-6 were significantly different between the two groups. Data are mean ± SD by Wilcoxon rank-sum test unless otherwise specified.